{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:26:06Z","timestamp":1785795966382,"version":"3.56.0"},"reference-count":40,"publisher":"Bentham Science Publishers Ltd.","issue":"10","funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["RSP-2019\/85"],"award-info":[{"award-number":["RSP-2019\/85"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2020,10,29]]},"abstract":"<jats:sec>\n<jats:title>Purpose:<\/jats:title>\n<jats:p>Hepatocellular carcinoma (HCC) is a common liver malignancy, which has a low\nsurvival rate of all cancers. 5-fluorouracil (5-FU) is clinically recognized to treat HCC. However, the\nsuccess of this therapy is highly limited due to rapid clearance and non- selective distribution. Cholesterol-\nconjugate (5-FUC) loaded liposomes proposed to facilitate the transport of 5-FUC into tumor cells\n<jats:italic>via<\/jats:italic> Low-Density Lipoprotein receptor (LDL receptor) that overexpressed in HCC. Thus, the aim of this\nstudy was to use 5-FUC loaded liposome as a promising strategy to combat HCC and improve the response\nof HCC to chemotherapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>5-FUC and 5-FU loaded liposomes were optimized based on Cholesterol (CHO) ratio and\ntype of phospholipid to achieve a potential effect on HCC. Liposomes were prepared by the thin-film\nhydration method, and evaluated in terms of particle size, polydispersity, zeta potential, Entrapment\nEfficiency (EE), morphology, drug release and cytotoxicity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The obtained liposomes had a suitable nano-range particle size with negative zeta potential,\nand acceptable EE%. <jats:italic>In vitro<\/jats:italic> drug release of 5-FUC loaded liposomes showed a lower cumulative release\nover 24 h as compared to 5-FU loaded liposomes. 5-FUC loaded liposomes exhibited a higher <jats:italic>in\nvitro<\/jats:italic> cytotoxic effect as compared to the free drug and 5-FU loaded liposomes against HepG2 cell lines\nafter 48 h <jats:italic>via<\/jats:italic> MTT assay.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>These results concluded that 5-FUC loaded liposomes could be used as an alternative tactic\nto increase the therapeutic index of 5-FU and pave the way for potential clinical applications.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201817666200211095452","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T14:51:53Z","timestamp":1581432713000},"page":"898-910","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cholesterol-Conjugate as a New Strategy to Improve the Cytotoxic Effect of 5-Fluorouracil on Liver Cancer: Impact of Liposomal Composition"],"prefix":"10.2174","volume":"17","author":[{"given":"Saleh Ayed","family":"Alanazi","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamaleldin Ibrahim","family":"Harisa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M.","family":"Badran","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazrul","family":"Haq","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awwad Abdoh","family":"Radwan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Kumar","sequence":"additional","affiliation":[{"name":"Vitiligo Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiyaz","family":"Shakeel","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fars Kaed","family":"Alanazi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Kayyali Chair for Pharmaceutical Industries, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3109\/02652048.2013.879929","volume":"31","author":"Dangi R.","year":"2014","unstructured":"Dangi R.; Hurkat P.; Jain A.; Shilpi S.; Jain A.; Gulbake A.; Jain S.K.; Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles. J Microencapsul 2014,31(5),479-487","journal-title":"J Microencapsul"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/diagnostics3010170","volume":"3","author":"Aravalli R.N.","year":"2013","unstructured":"Aravalli R.N.; Development of microRNA therapeutics for hepatocellular carcinoma. Diagnostics (Basel) 2013,3(1),170-191","journal-title":"Diagnostics (Basel)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/JHC.S106529","volume":"4","author":"Galun D.","year":"2017","unstructured":"Galun D.; Srdic-Rajic T.; Bogdanovic A.; Loncar Z.; Zuvela M.; Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017,4,93-103","journal-title":"J Hepatocell Carcinoma"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"16861","DOI":"10.1038\/srep16861","volume":"5","author":"Guo J.","year":"2015","unstructured":"Guo J.; Chen Q.; Lam C.W.; Wang C.; Wong V.K.; Xu F.; Jiang Z.; Zhang W.; Application of artificial neural network to investigate the effects of 5-fluorouracil on ribonucleotides and deoxyribonucleotides in HepG2 cells. Sci Rep 2015,5,16861","journal-title":"Sci Rep"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1186\/1471-2407-14-621","volume":"14","author":"McAlpine J.A.","year":"2014","unstructured":"McAlpine J.A.; Lu H.T.; Wu K.C.; Knowles S.K.; Thomson J.A.; Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. BMC Cancer 2014,14,621","journal-title":"BMC Cancer"},{"key":"ref=6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063093","volume":"8","author":"Chen X.","year":"2013","unstructured":"Chen X.; Ding G.; Gao Q.; Sun J.; Zhang Q.; Du L.; Qiu Z.; Wang C.; Zheng F.; Sun B.; Ni J.; Feng Z.; Zhu J.; A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma. PLoS One 2013,8(5)","journal-title":"PLoS One"},{"key":"ref=7","first-page":"157","volume":"678","author":"Wigmore P.M.","year":"2010","unstructured":"Wigmore P.M.; Mustafa S.; El-Beltagy M.; Lyons L.; Umka J.; Bennett G.;  2010,678,157-164"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jhep.2011.07.031","volume":"56","author":"Asghar U.","year":"2012","unstructured":"Asghar U.; Meyer T.; Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 2012,56(3),686-695","journal-title":"J Hepatol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1504\/IJNT.2012.049450","volume":"9","author":"Calderini A.","year":"2012","unstructured":"Calderini A.; Pessine B.T.; Franchi G.C.; Nowill A.E.; Preparation and characterisation of 5-fluorouracil containing PLGA nanospheres coated with chitosan for drug delivery. Int J Nanotechnol 2012,9,851-861","journal-title":"Int J Nanotechnol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1023\/A:1020651311866","volume":"20","author":"Presant C.A.","year":"2002","unstructured":"Presant C.A.; Jacobson J.; Wolf W.; Waluch V.; Weitz I.C.; Macdonald J.S.; Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? a Southwest oncology group study. Invest New Drugs 2002,20(4),369-376","journal-title":"Invest New Drugs"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"13177","DOI":"10.3390\/molecules190913177","volume":"19","author":"Radwan A.A.","year":"2014","unstructured":"Radwan A.A.; Alanazi F.K.; Design and synthesis of new cholesterol-conjugated 5-fluorouracil: a novel potential delivery system for cancer treatment. Molecules 2014,19(9),13177-13187","journal-title":"Molecules"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1515\/9783110873665-005","author":"Kostner G.M.","year":"1989","unstructured":"Kostner G.M.; Laggner P.;  Human plasma lipoprotein 1989,23-51","journal-title":"Human plasma lipoprotein"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/1097-0215(20010101)91:1<41::AID-IJC1009>3.0.CO;2-2","volume":"91","author":"Chen Y.","year":"2001","unstructured":"Chen Y.; Hughes-Fulford M.; Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int J Cancer 2001,91(1),41-45","journal-title":"Int J Cancer"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jsps.2013.12.015","volume":"22","author":"Harisa G.I.","year":"2014","unstructured":"Harisa G.I.; Alanazi F.K.; Low density lipoprotein bionanoparticles: from cholesterol transport to delivery of anti-cancer drugs. Saudi Pharm J 2014,22(6),504-515","journal-title":"Saudi Pharm J"},{"key":"ref=15","first-page":"248","volume":"10","author":"Ji B.","year":"2001","unstructured":"Ji B.; Lu D.R.; A novel approach to targeted drug delivery for treatment of brain cancer. J Cont Release 2001,10,248-268","journal-title":"J Cont Release"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.molliq.2015.06.069","volume":"211","author":"Shakeel F.","year":"2015","unstructured":"Shakeel F.; Alanazi F.K.; Raish M.; Haq N.; Radwan A.A.; Alsarra I.; Pharmacokinetic and in vitro cytotoxic evaluation of cholesterol-rich nanoemulsion of cholesteryl-succinyl-5-fluorouracil. J Mol Liq 2015,211,164-168","journal-title":"J Mol Liq"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1134\/S1061934815050056","volume":"70","author":"Alanazi F.K.","year":"2015","unstructured":"Alanazi F.K.; Haq N.; Radwan A.A.; Alsarra I.A.; Shakeel F.; Development and validation of UHPLC-DAD method for the determination of cholesteryl-hexahydrophthaloyl-5-fluorouracil in lipid nanoemulsion. J Anal Chem 2015,70,593-599","journal-title":"J Anal Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1073\/pnas.1018382108","volume":"108","author":"Wong C.","year":"2011","unstructured":"Wong C.; Stylianopoulos T.; Cui J.; Martin J.; Chauhan V.P.; Jiang W.; Popovic Z.; Jain R.K.; Bawendi M.G.; Fukumura D.; Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci USA 2011,108(6),2426-2431","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd2614","volume":"7","author":"Davis M.E.","year":"2008","unstructured":"Davis M.E.; Chen Z.G.; Shin D.M.; Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008,7(9),771-782","journal-title":"Nat Rev Drug Discov"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ijpharm.2018.09.047","volume":"551","author":"Farzaneh H.","year":"2018","unstructured":"Farzaneh H.; Ebrahimi Nik M.; Mashreghi M.; Saberi Z.; Jaafari M.R.; Teymouri M.; A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: from liposomal preparation to therapy. Int J Pharm 2018,551(1-2),300-308","journal-title":"Int J Pharm"},{"key":"ref=21","first-page":"2285","volume":"6","author":"Moura J.A.","year":"2011","unstructured":"Moura J.A.; Valduga C.J.; Tavares E.R.; Kretzer I.F.; Maria D.A.; Maranh\u00e3o R.C.; Novel formulation of a methotrexate derivative with a lipid nanoemulsion. Int J Nanomed 2011,6,2285-2295","journal-title":"Int J Nanomed"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"6343","DOI":"10.1038\/s41598-017-06445-z","volume":"7","author":"Alves A.C.","year":"2017","unstructured":"Alves A.C.; Magarkar A.; Horta M.; Lima J.L.F.C.; Bunker A.; Nunes C.; Reis S.; Influence of doxorubicin on model cell membrane properties: insights from in vitro and in silico studies. Sci Rep 2017,7(1),6343","journal-title":"Sci Rep"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"15702","DOI":"10.1021\/ja8065557","volume":"130","author":"Huang Z.","year":"2008","unstructured":"Huang Z.; Szoka F.C.; Jr Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties. J Am Chem Soc 2008,130(46),15702-15712","journal-title":"J Am Chem Soc"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101179","volume":"53","author":"Song M.","year":"2019","unstructured":"Song M.; Liang Y.; Li K.; Zhang J.; Zhang N.; Tian B.; HanHyaluronic acid, modified liposomes for targeted delivery of doxorubicin and paclitaxel to CD44 overexpressing tumor cells with improved dual-drugs synergistic effect. J Drug Deliv Sci Technol 2019,53","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ijbiomac.2016.11.098","volume":"95","author":"Badran M.M.","year":"2017","unstructured":"Badran M.M.; Mady M.M.; Ghannam M.M.; Shakeel F.; Preparation and characterization of polymeric nanoparticles surface modified with chitosan for target treatment of colorectal cancer. Int J Biol Macromol 2017,95,643-649","journal-title":"Int J Biol Macromol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1080\/13880209.2017.1322617","volume":"55","author":"Albadawi D.A.","year":"2017","unstructured":"Albadawi D.A.; Mothana R.A.; Khaled J.M.; Ashour A.E.; Kumar A.; Ahmad S.F.; Al-Said M.S.; Al-Rehaily A.J.; Almusayeib N.M.; Antimicrobial, anticancer, and antioxidant compounds from Premna resinosa growing in Saudi Arabia. Pharm Biol 2017,55(1),1759-1766","journal-title":"Pharm Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/21691401.2019.1577887","volume":"47","author":"AlQahtani S.A.","year":"2019","unstructured":"AlQahtani S.A.; Harisa G.I.; Badran M.M.; AlGhamdi K.M.; Kumar A.; Salem-Bekhit M.M.; Ahmad S.F.; Alanazi F.K.; Nano-erythrocyte membrane-chaperoned 5-fluorouracil liposomes as biomimetic delivery platforms to target hepatocellular carcinoma cell lines. Artif Cells Nanomed Biotechnol 2019,47(1),989-996","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jconrel.2016.02.007","volume":"226","author":"Wada S.","year":"2016","unstructured":"Wada S.; Yasuhara H.; Wada F.; Sawamura M.; Waki R.; Yamamoto T.; Harada-Shiba M.; Obika S.; Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides. J Control Release 2016,226,57-65","journal-title":"J Control Release"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.urolonc.2007.03.015","volume":"26","author":"Haley B.","year":"2008","unstructured":"Haley B.; Frenkel E.; Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008,26(1),57-64","journal-title":"Urol Oncol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4103\/0973-8398.76752","volume":"4","author":"Essa E.A.","year":"2010","unstructured":"Essa E.A.; Effect of formulation and processing variables on the particle size of sorbitan monopalmitate niosomes. Asian J Pharm 2010,4,227-233","journal-title":"Asian J Pharm"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.2147\/IJN.S60674","volume":"9","author":"Duangjit S.","year":"2014","unstructured":"Duangjit S.; Pamornpathomkul B.; Opanasopit P.; Rojanarata T.; Obata Y.; Takayama K.; Ngawhirunpat T.; Role of the charge, carbon chain length, and content of surfactant on the skin penetration of meloxicam-loaded liposomes. Int J Nanomed 2014,9,2005-2017","journal-title":"Int J Nanomed"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijpharm.2016.06.057","volume":"514","author":"Pereira S.","year":"2016","unstructured":"Pereira S.; Egbu R.; Jannati G.; Al-Jamal W.T.; Docetaxel-loaded liposomes: the effect of lipid composition and purification on drug encapsulation and in vitro toxicity. Int J Pharm 2016,514(1),150-159","journal-title":"Int J Pharm"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0009-3084(02)00176-7","volume":"122","author":"Epand R.M.","year":"2003","unstructured":"Epand R.M.; Epand R.F.; Maekawa S.; The arrangement of cholesterol in membranes and binding of NAP-22. Chem Phys Lipids 2003,122(1-2),33-39","journal-title":"Chem Phys Lipids"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1208\/s12249-009-9373-4","volume":"11","author":"Hosny K.M.","year":"2010","unstructured":"Hosny K.M.; Ciprofloxacin as ocular liposomal hydrogel. AAPS PharmSciTech 2010,11(1),241-246","journal-title":"AAPS PharmSciTech"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1081\/LPR-120039717","volume":"14","author":"Sezer A.D.","year":"2004","unstructured":"Sezer A.D.; Ba\u015f A.L.; Akbu\u011fa J.; Encapsulation of enrofloxacin in liposomes I: preparation and in vitro characterization of LUV. J Liposome Res 2004,14(1-2),77-86","journal-title":"J Liposome Res"},{"key":"ref=36","first-page":"101","volume":"5","author":"Panwar P.","year":"2010","unstructured":"Panwar P.; Pandey B.; Lakhera P.C.; Singh K.P.; Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomed 2010,5,101-108","journal-title":"Int J Nanomed"},{"key":"ref=37","first-page":"21","volume":"12","author":"Tabandeh H.","year":"2013","unstructured":"Tabandeh H.; Mortazavi S.A.; An investigation into some effective factors on encapsulation efficiency of alpha-tocopherol in MLvs and the release profile from the corresponding liposomal gel. Iran J Pharm Res 2013,12(Suppl.),21-30","journal-title":"Iran J Pharm Res"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/313961","volume":"E313961","author":"Aydin R.S.T.","year":"2012","unstructured":"Aydin R.S.T.; Pulat M.; 5-Fluorouracil encapsulated chitosan nanoparticles for pH-stimulated drug delivery: evaluation of controlled release kinetics. J Nanomater 2012,E313961,1-10","journal-title":"J Nanomater"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1016\/j.watres.2004.03.017","volume":"38","author":"Qiang Z.","year":"2004","unstructured":"Qiang Z.; Adams C.; Potentiometric determination of acid dissociation constants (pKa) for human and veterinary antibiotics. Water Res 2004,38(12),2874-2890","journal-title":"Water Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s13346-015-0220-8","volume":"5","author":"Briuglia M.L.","year":"2015","unstructured":"Briuglia M.L.; Rotella C.; McFarlane A.; Lamprou D.A.; Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv Transl Res 2015,5(3),231-242","journal-title":"Drug Deliv Transl Res"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179213","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/179213\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/179213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T11:19:02Z","timestamp":1616498342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179213\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,29]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201817666200211095452","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}